Review of the Proposed Generic Drug and Biosimilars User Fees and Further Examination of Drug Shortages PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Review of the Proposed Generic Drug and Biosimilars User Fees and Further Examination of Drug Shortages PDF full book. Access full book title Review of the Proposed Generic Drug and Biosimilars User Fees and Further Examination of Drug Shortages by United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health. Download full books in PDF and EPUB format.
Author: United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health
Publisher:
ISBN:
Category : Biological products
Languages : en
Pages : 210
Get Book Here
Book Description
Author: United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health
Publisher:
ISBN:
Category : Biological products
Languages : en
Pages : 210
Get Book Here
Book Description
Author: United States. Congress. House. Committee on Energy and Commerce
Publisher:
ISBN:
Category : Energy policy
Languages : en
Pages : 104
Get Book Here
Book Description
Author:
Publisher: Government Printing Office
ISBN:
Category :
Languages : en
Pages : 566
Get Book Here
Book Description
Author: United States. Congress
Publisher:
ISBN:
Category : Law
Languages : en
Pages : 2538
Get Book Here
Book Description
The Congressional Record is the official record of the proceedings and debates of the United States Congress. It is published daily when Congress is in session. The Congressional Record began publication in 1873. Debates for sessions prior to 1873 are recorded in The Debates and Proceedings in the Congress of the United States (1789-1824), the Register of Debates in Congress (1824-1837), and the Congressional Globe (1833-1873)
Author: United States. Congress. House. Committee on Energy and Commerce
Publisher:
ISBN:
Category :
Languages : en
Pages : 1064
Get Book Here
Book Description
Author: National Academies of Sciences, Engineering, and Medicine
Publisher: National Academies Press
ISBN: 0309468086
Category : Medical
Languages : en
Pages : 235
Get Book Here
Book Description
Thanks to remarkable advances in modern health care attributable to science, engineering, and medicine, it is now possible to cure or manage illnesses that were long deemed untreatable. At the same time, however, the United States is facing the vexing challenge of a seemingly uncontrolled rise in the cost of health care. Total medical expenditures are rapidly approaching 20 percent of the gross domestic product and are crowding out other priorities of national importance. The use of increasingly expensive prescription drugs is a significant part of this problem, making the cost of biopharmaceuticals a serious national concern with broad political implications. Especially with the highly visible and very large price increases for prescription drugs that have occurred in recent years, finding a way to make prescription medicinesâ€"and health care at largeâ€"more affordable for everyone has become a socioeconomic imperative. Affordability is a complex function of factors, including not just the prices of the drugs themselves, but also the details of an individual's insurance coverage and the number of medical conditions that an individual or family confronts. Therefore, any solution to the affordability issue will require considering all of these factors together. The current high and increasing costs of prescription drugsâ€"coupled with the broader trends in overall health care costsâ€"is unsustainable to society as a whole. Making Medicines Affordable examines patient access to affordable and effective therapies, with emphasis on drug pricing, inflation in the cost of drugs, and insurance design. This report explores structural and policy factors influencing drug pricing, drug access programs, the emerging role of comparative effectiveness assessments in payment policies, changing finances of medical practice with regard to drug costs and reimbursement, and measures to prevent drug shortages and foster continued innovation in drug development. It makes recommendations for policy actions that could address drug price trends, improve patient access to affordable and effective treatments, and encourage innovations that address significant needs in health care.
Author: Dave Tarr
Publisher: CQ Press
ISBN: 145227035X
Category : Political Science
Languages : en
Pages : 1105
Get Book Here
Book Description
Chronicling the highly partisan and polarized environment during the historic first term of President Barack Obama, Congress and the Nation 2009-2012 Volume XIII is the most authoritative reference on congressional law-making and trends during the 111th and 112th Congresses. The newest edition in this award-winning series documents the most fiercely debated issues during this period, including: Stimulus spending in the wake of financial crisis The controversial reform of the U.S. healthcare system Showdowns over raising the national debt ceiling Extensions of tax cuts and unemployment compensation Confirmation of two new female members of the U.S. Supreme Court Overhaul of financial industry regulations Repeal of the “don’t ask, don’t tell” law banning openly gay armed forces personnel from military service This acclaimed resource also covers the shift in partisan control of the U.S. House after the 2010 midterm election and the subsequent gridlock for lawmaking in the 112th Congress. Organized by policy area, each chapter summarizes the legislative activity, including a chronology and legislative history of the bills passed and the major provisions of the final laws. No other source guides readers seamlessly through the policy output of the national legislature with the breadth, depth, and authority of Congress and the Nation. This must-have reference for all academic libraries meets the needs of the full spectrum of users, from lower-level undergraduates through researchers and faculty.
Author:
Publisher:
ISBN:
Category :
Languages : en
Pages : 1440
Get Book Here
Book Description
Author: Margaret A. Hamburg
Publisher: DIANE Publishing
ISBN: 1437988377
Category : Medical
Languages : en
Pages : 37
Get Book Here
Book Description
This report presents a new strategy by the Food and Drug Admin. (FDA) to meet the challenges posed by rapidly rising imports of FDA-regulated products and a complex global supply chain. The agency is planning to transform the way it conducts business and to act globally in order to promote and protect the health of U.S. consumers. Highlights of the report include four key elements needed to make the change: (1) The FDA will partner with its counterparts worldwide to create global coalitions of regulators focused on ensuring and improving global product safety and quality; (2) The coalitions of regulators will develop international data information systems and networks and increase the regular and proactive sharing of data and regulatory resources across world markets; (3) The FDA will build in additional information gathering and analysis capabilities with an increased focus on risk analytics and IT; (4) The FDA increasingly will leverage the efforts of public and private third parties and industry and allocate FDA resources based on risk. The report also discusses trends expected to be seen worldwide in upcoming years which have caused FDA to develop its new strategy. Figures. This is a print on demand report.
Author:
Publisher: World Health Organization
ISBN: 9240011870
Category : Business & Economics
Languages : en
Pages : 70
Get Book Here
Book Description
In recent years, high prices of pharmaceutical products have posed challenges in high- and low-income countries alike. In many instances, high prices of pharmaceutical products have led to significant financial hardship for individuals and negatively impacted on healthcare systems' ability to provide population-wide access to essential medicines. Pharmaceutical pricing policies need to be carefully planned, carried out, and regularly checked and revised according to changing conditions. Strong, well-thought-out policies can guide well-informed and balanced decisions to achieve affordable access to essential health products. This guideline replaces the 2015 WHO guideline on country pharmaceutical pricing policies, revised to reflect the growing body of literature since the last evidence review in 2010. This update also recognizes country experiences in managing the prices of pharmaceutical products.
